This trial will test a new vaccine to see if it is safe and effective against meningococcal disease, which is a serious infection.
6 Primary · 2 Secondary · Reporting Duration: At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
Experimental Treatment
300 Total Participants · 2 Treatment Groups
Primary Treatment: MenABCWY vaccine · Has Placebo Group · Phase 2
Age 11 - 14 · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Utah | 50.0% |
Nebraska | 50.0% |
< 18 | 100.0% |
GSK Investigational Site | 100.0% |
Did not meet criteria | 100.0% |